

22 June 2026

Osteopore completes its first custom orthopaedic reconstruction in Hong Kong

Highlights

- Osteopore is delighted to announce the completion of the first orthopaedic reconstruction case in Hong Kong.
- The surgery, a correction of deformity at the patient's wrist, was performed at Queen Mary Hospital by Clinical Associate Professor Christian Fang Xinshuo, who is also leading efforts at the Tam Shui Anatomical Modelling Laboratory.
- This also marks the first collaboration milestone between Osteopore and the Tam Shui Anatomical Modelling Laboratory.

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX: OSX; Osteopore or Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the successful completion of the first orthopaedic reconstruction case in Hong Kong, following the signing of an exclusive agreement with MontsMed Hong Kong Company Limited (MontsMed).

As previously announced on 22 January 2026¹, Osteopore expanded its orthopaedic business into Hong Kong through an exclusive distribution agreement with MontsMed focusing on orthopaedic trauma reconstruction market. This segment represents a significant commercial opportunity for Osteopore. The successful completion of this first case makes an important

¹ ASX announcement, "OSX strikes agreement for orthopaedic products in Hong Kong", 22 January 2026.



milestone in Osteopore's expansion in Hong Kong and highlights the growing clinical adoption of its regenerative implant technology.

It also represents the first milestone under the collaboration between Osteopore and the Tam Shui Anatomical Modelling Laboratory (Tam Shui AML), as announced on 30 January 2026². This partnership focuses on co-developing, testing, validating, adopting and scaling customised medical devices by combining Osteopore's expertise in 3D-printed regenerative implants with Tam Shui AML's advanced anatomical modelling capabilities.

The surgery, a correction of deformity at the patient's wrist, was performed at Queen Mary Hospital by Clinical Associate (Cl. Assoc.) Professor Christian Fang Xinshuo, Deputy Chief of the Division of Orthopaedic Trauma at University of Hong Kong. Despite the complexity of the correction, the design of this custom implant was completed within a day – allowing Cl. Assoc. Professor Fang to optimise the scheduling of surgery for this patient.

Based on data published by the Hospital Authority (HA)³, a Hong Kong statutory body established under the Hospital Authority Ordinance in 1990, there were approximately 106,000 new cases in orthopaedic and traumatology in 2024.

The Asia Pacific bone graft and substitutes market was estimated to be USD 662m in 2024, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.2% from 2025 to 2030, driven by increasing prevalence of orthopaedic disorders and musculoskeletal injuries⁴.

Although Hong Kong is a relatively small market, it holds strategic importance to China as a potential gateway to the Greater Bay Area. The potential benefits include regulatory

² ASX announcement, "OSX bolsters digital design, eyes HK Centre of Excellence", 30 January 2026.

³ https://www.ha.org.hk/visitor/ha_visitor_index.asp?Content_ID=10008&Lang=ENG&Dimension=100&Parent_ID=10004

⁴ <https://www.grandviewresearch.com/industry-analysis/asia-pacific-bone-grafts-substitutes-market>



harmonisation initiatives that facilitate cross-border use of medical devices and collaborative innovation across the region's extensive healthcare infrastructure⁵.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Mark Leong

Executive Chairman

Osteopore Limited

E: mark_leong@osteopore.com

⁵ <https://www.bayarea.gov.hk/gbais/tc/development/medical-co-operation/allowing-designated-healthcare-institutions-in-the-greater-bay-area-to-use-hong-kong-registered-drugs-and-medical-devices/>



About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

